Literature DB >> 15545059

Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?

Sophie Ohlsson1, Jörgen Wieslander, Mårten Segelmark.   

Abstract

AIMS: The anti-neutrophilic cytoplasmatic autoantibody-associated vasculitides (AASV) are diseases of relapsing-remitting inflammation. Here we explore the cytokine profile in different phases of disease, looking for pathogenic clues of possible prognostic value.
RESULTS: Interleukin (IL)-6, IL-8 and IL-10 were significantly elevated in plasma. Patients in the stable phase who subsequently developed adverse events had higher IL-8 values. Patients in the stable phase who relapsed within 3 months had lower IL-10 values and higher IL-6 levels.
CONCLUSIONS: Patients with AASV have raised circulating cytokine levels compared with healthy controls, even during remission. Raised IL-8 seems associated with poor prognosis. Lower levels of IL-10 and higher levels of IL-6 herald a greater risk of relapse. Patients with systemic vasculitis in clinical remission have persistent disease activity, kept under control by inhibitory cytokines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545059      PMCID: PMC1781567          DOI: 10.1080/09629350400003100

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  32 in total

Review 1.  Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes.

Authors:  F Ferrario; M P Rastaldi
Journal:  Nephrol Dial Transplant       Date:  1999-07       Impact factor: 5.992

Review 2.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

Authors:  J S Yudkin; M Kumari; S E Humphries; V Mohamed-Ali
Journal:  Atherosclerosis       Date:  2000-02       Impact factor: 5.162

3.  Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients.

Authors:  Peter R Lowe; Helen F Galley; Ashraf Abdel-Fattah; Nigel R Webster
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

4.  Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis.

Authors:  G Muraközy; K I Gaede; B Ruprecht; O Gutzeit; M Schürmann; A Schnabel; M Schlaak; W L Gross; J Müller-Quernheim
Journal:  J Mol Med (Berl)       Date:  2001-11       Impact factor: 4.599

Review 5.  How and why should we detect ANCA?

Authors:  M Segelmark; K Westman; J Wieslander
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

Review 6.  Neopterin measurement in clinical diagnosis.

Authors:  A Berdowska; K Zwirska-Korczala
Journal:  J Clin Pharm Ther       Date:  2001-10       Impact factor: 2.512

7.  Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene.

Authors:  Yihua Zhou; Ricardo Giscombe; Deren Huang; Ann Kari Lefvert
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

8.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.

Authors:  Vikas R Dharnidharka; Charles Kwon; Gary Stevens
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

9.  Wegener's granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation.

Authors:  Katja Hattar; Annette Bickenbach; Elena Csernok; Simone Rosseau; Ulrich Grandel; Werner Seeger; Friedrich Grimminger; Ulf Sibelius
Journal:  J Leukoc Biol       Date:  2002-06       Impact factor: 4.962

10.  Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days.

Authors:  Daniel G Remick; Gerald R Bolgos; Javed Siddiqui; Jungsoon Shin; Jean A Nemzek
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

View more
  24 in total

1.  Increased neutrophil membrane expression and plasma level of proteinase 3 in systemic vasculitis are not a consequence of the - 564 A/G promotor polymorphism.

Authors:  M Abdgawad; T Hellmark; L Gunnarsson; K W A Westman; M Segelmark
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

3.  Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.

Authors:  Gunnar Tomasson; Michael Lavalley; Kahraman Tanriverdi; Javier D Finkielman; John C Davis; Gary S Hoffman; W Joseph McCune; E William St Clair; Ulrich Specks; Robert Spiera; John H Stone; Jane E Freedman; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-03-16       Impact factor: 4.666

4.  The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell R Schroeder; Brian F Kabat; Carol A Langford; Cees G M Kallenberg; Philip Seo; Robert F Spiera; E William St Clair; Fernando C Fervenza; John H Stone; Paul A Monach; Ulrich Specks; Peter A Merkel
Journal:  J Autoimmun       Date:  2019-07-15       Impact factor: 7.094

5.  High serum hepcidin is associated with the occurrence of anemia in anti-myeloperoxidase antibody-associated vasculitis with normal kidney function: a cross-sectional study.

Authors:  Tong Chen; Peng-Cheng Xu; Shui-Yi Hu; Shan Gao; Jun-Ya Jia; Tie-Kun Yan
Journal:  Rheumatol Int       Date:  2019-03-29       Impact factor: 2.631

6.  AP-VAS 2012 case report: a case of ANCA-negative pauci-immune crescentic glomerulonephritis associated with IL-6-producing adenosquamous cell carcinoma of the lung.

Authors:  Takashi Morikawa; Atsuhiro Yoshida; Shinya Kobayashi; Mikiko Shibata; Masahiro Hamada; Masatsugu Kishida; Chizuko Kitabayashi; Haruko Daga; Yoshio Konishi; Koji Takeda; Masahito Imanishi
Journal:  CEN Case Rep       Date:  2013-03-14

Review 7.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

8.  Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.

Authors:  Paul A Monach; Roscoe L Warner; Gunnar Tomasson; Ulrich Specks; John H Stone; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Jeffrey Krischer; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Kent J Johnson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2012-09-12       Impact factor: 19.103

9.  A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

Authors:  T Kurz; M Weiner; C Skoglund; S Basnet; P Eriksson; M Segelmark
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

10.  Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.

Authors:  Sophie Ohlsson; Omran Bakoush; Jan Tencer; Ole Torffvit; Mårten Segelmark
Journal:  Mediators Inflamm       Date:  2009-07-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.